| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| P819 | ADS bibcode | 2014PLoSO...9j1253W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0101253 |
| P932 | PMC publication ID | 4077727 |
| P698 | PubMed publication ID | 24983855 |
| P5875 | ResearchGate publication ID | 263586156 |
| P2093 | author name string | Jin Li | |
| Xiaoyan Liu | |||
| Bin Wu | |||
| Haixiang Wu | |||
| Houwen Lin | |||
| P2860 | cites work | A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard | Q21090878 |
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 | ||
| Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 | ||
| Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results | Q24633874 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation. | Q50498550 | ||
| Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. | Q50511227 | ||
| Bevacizumab versus ranibizumab: why are we not playing the joker? | Q51034328 | ||
| Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. | Q53362175 | ||
| Off-label prescribing in macular degeneration. | Q54617138 | ||
| Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema | Q84242266 | ||
| Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization | Q84871205 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 | ||
| Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial | Q28294611 | ||
| Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial | Q28294837 | ||
| Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis | Q28534015 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis | Q31076710 | ||
| Role of vascular endothelial growth factor in ocular angiogenesis | Q33255417 | ||
| A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections | Q33982800 | ||
| The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review | Q34378757 | ||
| A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration | Q34537737 | ||
| Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study | Q34913612 | ||
| Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy | Q35820349 | ||
| Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy | Q35999201 | ||
| Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration | Q36619213 | ||
| Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients | Q36788529 | ||
| The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study | Q37061085 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. | Q37582957 | ||
| Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file | Q37839380 | ||
| Bias in location and selection of studies | Q41694445 | ||
| Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial | Q43155615 | ||
| Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders | Q44150789 | ||
| Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration | Q44249268 | ||
| A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema | Q46426474 | ||
| Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial | Q47857376 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | globulins | Q321710 |
| bevacizumab | Q413299 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| neovascularization | Q1281049 | ||
| eye disease | Q3041498 | ||
| retinal neovascularization | Q42293706 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e101253 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials | |
| P478 | volume | 9 |
Search more.